

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
022410Orig1s000

OTHER REVIEW(S)



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: June 8, 2010

To: Bob Rappaport, MD, Division Director
**Division of Anesthesia and Analgesia
Products (DAAP)**

Through: Mary Willy, PhD, Deputy Director
Division of Risk Management (DRISK)

Sharon R. Mills, BSN, RN, CCRP
Senior Patient Labeling Reviewer, Acting Team
Leader
Division of Risk Management

From: Latonia M. Ford, RN, BSN, MBA
Patient Product Information Reviewer
Division of Risk Management

Subject: Addendum to DRISK Review of Patient Labeling
(Medication Guide), dated August 6, 2009

Drug Name(s): Suboxone (buprenorphine and naloxone)
sublingual film

Application Type/Number: NDA 22-410

Applicant/sponsor: Reckitt Benckiser Pharmaceuticals Inc.

OSE RCM #: 2010-970

1 INTRODUCTION

This review is written as an addendum to the Division of Risk Management (DRISK) review of the MG for Suboxone (buprenorphine and naloxone) sublingual film, originally requested by the Division of Anesthesia and Analgesia Products (DAAP), and completed on August 6, 2009.

Please let us know if DAAP would like a meeting to discuss this review or any of our changes prior to sending to the Applicant.

2 MATERIAL REVIEWED

Draft Suboxone (buprenorphine and naloxone) sublingual flim Medication Guide (MG) submitted on October 20, 2008, revised by DRISK on August 6, 2009, and further revised by the review division and provided to DRISK on May 14, 2010.

3 RESULTS OF REVIEW

In our review of the MG, we have:

- simplified wording and clarified concepts where possible
- ensured that the MG is consistent with the PI
- removed unnecessary or redundant information
- ensured that the MG meets the Regulations as specified in 21 CFR 208.20
- ensured that the MG meets the criteria as specified in FDA's Guidance for Useful Written Consumer Medication Information (published July 2006)

After the original MG review was completed on August 6, 2009, DAAP sent the Applicant a Complete Response (CR) letter on August 21, 2009 because the proposed REMS was not sufficient to ensure that the benefits of suboxone sublingual film outweigh the risks associated with the use of the drug. DRISK revisions of the MG from August 6, 2009 were not provided to the Applicant. We received comments from DAAP on May 14, 2010 in response to our MG review completed on August 6, 2009. These comments and revisions are the subject of this review addendum.

Our annotated MG is appended to this memo. We retained all of our previous comments as well as the comments from DAAP in the tracked changes version of the MG.

Any additional revisions to the PI should be reflected in the MG.

Please let us know if you have any questions.

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22410	ORIG-1	RECKITT BENCKISER PHARMACEUTICA LS INC	SUBOXONE (BUPRENORPHINE/NALOXONE) sublingual film

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LATONIA M FORD


06/08/2010

Suboxone Addendum to DRISK Review of Patient Labeling (Medication Guide), dated August 6, 2009

MARY E WILLY

06/08/2010

I concur



Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology

Date: August 6, 2009

To: Bob Rappaport, MD, Division Director
**Division of Anesthesia, Analgesia, and Rheumatology
Products (DAARP)**

Through: Claudia Karwoski, PharmD, Director
Division of Risk Management (DRISK)
Jodi Duckhorn, MA, Team Leader
Division of Risk Management

From: Latonia M. Ford, RN, BSN, MBA
Patient Product Information Reviewer
Division of Risk Management

Subject: DRISK Review of Patient Labeling (Medication Guide)

Drug Name(s): Buprenorphine and Naloxone (Suboxone)

Application Type/Number: NDA 22-410

Applicant/sponsor: Reckitt Benckiser Pharmaceuticals INC.

OSE RCM #: 2009-2042

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.